Breast Cancer Clinical Trial Sentiment
See what key opinion leaders such as Dr. Stephanie L. Graff, Dr. Sara M. Tolaney, Dr. Heather Lynn McArthur, Dr. Rohit Gosain, Dr. Hope S. Rugo and others are saying about the results of the most recent breast cancer clinical trials.
KEYNOTE-522 - FREE ACCESS
The KEYNOTE-522 trial has been a focal point of discussion in the oncology community, with significant results presented at the recent #ESMO24 conference. This Phase III trial, presented by Prof. Peter Schmid from @QMBCI, has demonstrated impressive outcomes in the treatment of high-risk early-stage triple-negative breast cancer (TNBC).
Read more
monarchE
monarchE is a randomized, phase III clinical trial of adjuvant abemaciclib (Verzenio) plus endocrine therapy for HR+, HER2-, high-risk early breast cancer. The FDA granted an approval to Verzenio as a result of the monarchE clinical trial results. Dr. Stephen Johnston, of the Royal Marsden NHS Foundation Trust, led the trial.
Read more
NATALEE
NATALEE is a phase III trial of adjuvant ribociclib (Kisqali) + endorcrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer. The NATALEE trial is led by Dr. Dennis Slamon from the University of Los Angeles (UCLA).
Read more
TROPION-Breast01
TROPION-Breast01 is a phase III study of datopotamab deruxtecan (Enhertu) vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer. The clinical trial is led by Dr. Aditya Bardia of UCLA who presented the clinical trial at #ESMO23 and #SABC23.
Read more